BOPA needs YOU!

BOPA needs YOU!
 
We have been asked to write a chapter for an IAEA/WHO publication, describing the pharmacy service requirements for a cancer centre.  I would like to pull together a small taskforce of BOPA members with experience in setting up or managing an oncology pharmacy service to write the chapter together.  A taskforce Chair will be appointed from within the group
 
The chapter will include all the types of pharmacy resource needed for a centre, not just the chemo side.  It is up to the authors to decide and improve, but it could be structured to include:
 

  • Infrastructure (spaces, ventilation, adjacencies to other services etc.)
  • Equipment – certainly including hoods etc, but all other preparation and dispensing equipment
  • Human resources (numbers in relation to throughput, qualification mix etc.)
  • Quality Assurance processes recommended
  • Clinical pharmacy services

 
It sounds a lot, but is an overview so the recommended length is 10 pages – it would be a summary which outlines the building blocks of a core pharmacy service rather than an educational guide for any actual step.
 
Unfortunately it is unpaid, but the writers would of course be named as  co-authors.  The first drafts are meant to be in by 15th July
 
If you are interested please contact [email protected],uk by Friday 3rd May
 
 
Emma Foreman (BOPA co-chair)
Consultant Pharmacist
Pharmacy Department

The Royal Marsden NHS Foundation Trust
Tel: 0208 6426011 ext 1067
Email: [email protected]
 
Pharmacy Vision
To provide pioneering and compassionate medicines optimisation services.
 

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article